Opportunity for Improved Menopausal Hormone Therapy Prescribing
JAMA · 21.04.2026 · 335 (15) · 1297
DOI: 10.1001/jama.2026.1891 ↗Kurz gefasst
Fachartikel in der Zeitschrift JAMA, erschienen am 21.04.2026. Verfasst von Deborah Bartz und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Obstetrics and Gynecology, Brigham and Women's Hospital, Boston, Massachusetts. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 25 Literaturangaben.
Abstract (Originalsprache)
This Perspective discusses the implications of the recent US Food and Drug Administration (FDA) label change on menopausal hormone therapy for clinicians to better integrate hormone therapy options and personalized, shared decision-making to improve care for midlife women.
Autor:innen und Institutionen
- Department of Obstetrics and Gynecology, Brigham and Women's Hospital, Boston, Massachusetts.
- Connors Center for Women's Health Research, Brigham and Women's Hospital, Boston, Massachusetts.
- Harvard Medical School, Boston, Massachusetts.
- Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts.
Zitieren
APA
Bartz, D., Tadikonda, A., & Manson, J. E. (2026). Opportunity for Improved Menopausal Hormone Therapy Prescribing. JAMA, 335(15), 1297. https://doi.org/10.1001/jama.2026.1891
Vancouver
Bartz D, Tadikonda A, Manson JE. Opportunity for Improved Menopausal Hormone Therapy Prescribing. JAMA. 2026;335(15):1297. doi:10.1001/jama.2026.1891
BibTeX
@article{Bartz2026,
author = {Bartz, Deborah and Tadikonda, Ananya and Manson, JoAnn E},
title = {Opportunity for Improved Menopausal Hormone Therapy Prescribing},
journal = {JAMA},
year = {2026},
volume = {335},
number = {15},
pages = {1297},
doi = {10.1001/jama.2026.1891}
}
EUVIMED